NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
+1 more ↓
69%
Finnrick rating
#222 of 345 ranked vendors
32 of 47 classifiable tests passed
methodology · Purity focus
Finnrick analysis

ZZQ Peptides shows its strongest purity-focus evidence in GHK-Cu and Retatrutide, where later results are mostly passing despite earlier fill, identity, and batch-ID outliers. Tirzepatide is more volatile, and Tesamorelin is the weakest line with repeated purity misses; the record is current and fairly broad, but documentation and failures remain uneven.

methodology →
vendor intelligence report
Vendor Intelligence Report: ZZQ Peptides

We investigated who actually operates ZZQ Peptides — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

31 pages7 risk factors assessed12 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
86%
6
2
Retatrutide
$0.57
81%
17
3
Tirzepatide
$0.55
64%
20
5
BPC-157
$0.85
-
0
7
Semaglutide
$0.60
-
0
9
TB-500
-
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%9 Oct 2025: 75%23 Oct 2025: 80%6 Dec 2025: 80%16 Dec 2025: 81%17 Dec 2025: 68%17 Dec 2025: 68%17 Dec 2025: 68%29 Dec 2025: 69%1 Jan 2026: 69%6 Jan 2026: 68%9 Jan 2026: 68%29 Jan 2026: 68%2 Feb 2026: 70%18 Feb 2026: 69%18 Feb 2026: 68%18 Feb 2026: 69%18 Feb 2026: 69%20 Feb 2026: 69%20 Feb 2026: 70%20 Feb 2026: 69%4 Mar 2026: 68%4 Mar 2026: 67%4 Mar 2026: 66%4 Mar 2026: 65%10 Mar 2026: 66%10 Mar 2026: 65%18 Mar 2026: 65%25 Mar 2026: 65%28 Apr 2026: 66%28 Apr 2026: 65%28 Apr 2026: 65%28 Apr 2026: 66%6 May 2026: 66%8 May 2026: 67%18 May 2026: 67%18 May 2026: 67%24 Jun 2026: 68%26 Jun 2026: 68%4 Aug 2026: 68%27 Aug 2026: 67%28 Sept 2026: current 69%75%69%69%Oct 25Sep 26
Free peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
ZZQ Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
27 Aug 2026
Fail
Tirzepatide
lab nameView COA
4 Aug 2026
Pass
Retatrutide
lab nameView COA
26 Jun 2026
Pass
Tirzepatide
lab nameView COA
24 Jun 2026
Pass
Retatrutide
lab nameView COA
24 May 2026
Incomplete
Tirzepatide
lab nameView COA
18 May 2026
Pass
Tirzepatide
lab nameView COA
18 May 2026
Pass
Tirzepatide
lab nameView COA
8 May 2026
Pass
Retatrutide
lab nameView COA
6 May 2026
Pass
Tirzepatide
lab nameView COA
28 Apr 2026
Pass
Tirzepatide
lab nameView COA
1-10 of 48

About ZZQ Peptides test results from Finnrick

ZZQ Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 4 peptides and 48 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible ZZQ Peptides peptides in this dataset are GHK-Cu (6 tests), Retatrutide (17 tests) and Tesamorelin (5 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 48 recent tests.

Corrections
No corrections.
Free peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply